Posts

Flagship combines three biotech platforms to launch AI drug-discovery company Etcelera

on
On October 29, 2026, Flagship Pioneering announced Etcelera, a new drug-discovery company formed by combining the platforms of Cellarity, Etiome, and Empress Therapeutics with Flagship’s in-house AI capabilities. Etcelera aims to use AI and biological data to identify disease drivers, predict how cells respond to interventions, and discover small-molecule medicines it believes may have better prospects in clinical development. Its platform brings together human-cell transcriptomic data, chemoproteomics, and large-scale cell-perturbation data. Flagship says it draws on more than 20 years of combined data, a model trained on data from 150 million cells, and more than 30 proprietary prediction models. The company is led by Adrian “Ad” Rawcliffe, formerly CEO of Adaptimmune. Its initial focus areas include blood disorders, metabolism, and immunology, with programs including myelofibrosis and essential thrombocythemia. No new funding was announced at launch. BioPharma Dive reported ...

Aspen raises $141M and Bambusa brings in $169M in biotech IPOs

on

FDA draft proposes a streamlined route for some patient-specific gene-editing therapies

on

Oura and UC San Diego Health launch smart-ring study of obesity treatment outcomes

on

HHS eases enforcement for six unapproved wellness peptides

on

Merck plans another investment-heavy year in 2027

on

Bristol Myers beats Q3 revenue estimates, but Cobenfy sales disappoint

on

LENZ cuts workforce as it shifts toward consumer marketing

on

Anthropic pushes further into biotech with one-person startup acquisition

on

Lilly raises revenue outlook again as Mounjaro and Zepbound demand drives a strong quarter

on

Cash-pay is becoming a key growth channel for Lilly’s weight-loss drugs

on

Flood damage at Pfizer–Zydus India plant may prolong cancer drug shortages

on

Enveda and Anthropic use Claude to speed drug-development paperwork

on